BioAtla Inc (NASDAQ:BCAB) has a beta value of 0.91 and has seen 1.36 million shares traded in the recent trading session. The company, currently valued at $28.26M, closed the recent trade at $0.48 per share which meant it gained $0.07 on the day or 18.30% during that session. The BCAB stock price is -427.08% off its 52-week high price of $2.53 and 50.0% above the 52-week low of $0.24. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.28 million shares traded. The 3-month trading volume is 553.89K shares.
The consensus among analysts is that BioAtla Inc (BCAB) is Buy stock at the moment, with a recommendation rating of 1.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
BioAtla Inc (NASDAQ:BCAB) trade information
Over the past 30 days, the shares of BioAtla Inc (NASDAQ:BCAB) have changed -2.67%. Short interest in the company has seen 4.34 million shares shorted with days to cover at 7.85.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 90.4% from the levels at last check today.. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is -941.67% off the targeted high while a plunge would see the stock gain -941.67% from the levels at last check today..
BioAtla Inc (BCAB) estimates and forecasts
The company’s shares have lost -69.18% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -10.97% over the past 5 years. Earnings growth for 2025 is a modest 19.44% while over the next 5 years, the company’s earnings are expected to increase by 8.86%.
BCAB Dividends
BioAtla Inc is expected to release its next earnings report on 2025-May-05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
BioAtla Inc (NASDAQ:BCAB)’s Major holders
Insiders own 10.90% of the company shares, while shares held by institutions stand at 32.92% with a share float percentage of 36.95%. Investors are also buoyed by the number of investors in a company, with BioAtla Inc having a total of 56.0 institutions that hold shares in the company. The top two institutional holders are SOLEUS CAPITAL MANAGEMENT, L.P. with over 3.9 million shares worth more than $5.34 million. As of 2024-06-30, SOLEUS CAPITAL MANAGEMENT, L.P. held 8.0915% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 1.89 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.58 million and represent 3.9101% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 2.08% shares in the company for having 1.22 shares of worth $0.59 million while later fund manager owns 549.45 shares of worth $0.27 million as of Mar 31, 2025 , which makes it owner of about 0.94% of company’s outstanding stock.
